PHARMA MAR (PHM.MC) -- ehemals Zeltia (Seite 92)

[bonDiacomova]

PHARMAMAR'S PM01183 FOR TREATING OVARIAN CANCER
RECEIVES A POSITIVE OPINION FOR ORPHAN DRUG STATUS
FROM THE EMA COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS

http://www.zeltia.com/

[bonDiacomova]

in welche richtung es langfristig gehen wird
entscheidet sich m.e. diesen herbst

1.) die probleme von j&j mit doxil bzw caelix sollen geloest werden/woden sein
2.) ergebnisse der IIb studie Nypta / Alzheimer: Oct. 2012
3.) erbebnisse der fase III studie Aplidin en mieloma múltiple im Oct/Nov 2012
4.) ergebnisse fase III Yondelis en primera línea de sarcomas: Oct/Nov 2012
5.) PM01183 das gleiche der FDA von gestern in europa,
6.) PM01183 ergebnisse cáncer de ovario, pulmón, mama und nuevos estudios... etc.

http://www.cincodias.com/articulo/ciencia-salud/octubre-deci…

[bonDiacomova]

Madrid, 29 August 2012:

The US Food and Drug Administration (FDA) has notified PharmaMar,
a biopharmaceutical subsidiary of Grupo Zeltia (ZEL.MC),
that it has been granted orphan drug status for PM01183
(lurbinectidin) for the treatment of ovarian cancer.

PM01183 (lurbinectedin) is the result of PharmaMar's internal drug discovery
and development efforts. PM01183 is currently in Phase II clinical trials for
relapsed ovarian, lung and breast cancers. PM01183 is also undergoing Phase I
development in combination with other chemotherapies and in haematological tumours.

engl : http://www.zeltia.com/Index.cfm?idIdioma=2


http://graficos.invertia.com/scripts/GrInterdia.dll?idtel=RV…

[bonDiacomova]

Antwort auf Beitrag Nr.: 43.095.062 von bonDiacomova am 27.04.12 07:13:53

halbjahres zahlen englisch
http://www.zeltia.com/analistas_inversores.cfm

klicken links auf
LATEST FINANCIAL REPORTS
2Q 2012

Q I 2009 - 8,3 mil
Q II 2009 - 11,1 mil
Q III 2009 - 11,0 mil
Q IIII 2009 - 13,4 mil

ges 2009 - 43,8 mil

Q I 2010 - 16,6 mil
Q II 2010 - 17,0 mil
Q III 2010 - 18,2 mil
Q IIII 2010 - 20,5 mil

ges 2010 - 72,3 mil

Q I 2011 - 19,6 mil
Q II 2011 - 18,6 mil
Q III 2011 - 18,4 mil
Q IIII 2011 - 17,5 mil

ges 2011 - 74,1 mil

Q I 2012 - 16,4 mil
Q II 2012 - 16,2 mil

[bonDiacomova]

Q I 2009 - 8,3 mil
Q II 2009 - 11,1 mil
Q III 2009 - 11,0 mil
Q IIII 2009 - 13,4 mil

ges 2009 - 43,8 mil

Q I 2010 - 16,6 mil
Q II 2010 - 17,0 mil
Q III 2010 - 18,2 mil
Q IIII 2010 - 20,5 mil

ges 2010 - 72,3 mil

Q I 2011 - 19,6 mil
Q II 2011 - 18,6 mil
Q III 2011 - 18,4 mil
Q IIII 2011 - 17,5 mil

ges 2011 - 74,1 mil

O I 2012 - 16,4 mil

afectadas por la falta de suministro de Caelix

Las ventas de PharmaMar en el primer trimestre del año pasado,
que ascendieron a 19,6 millones de euros,
incluían 2,4 millones de euros de venta
de materia prima a Johnson&Johnson.

[bonDiacomova]

Madrid, 23 abr
http://www.expansion.com/agencia/efe/2012/04/23/17181914.htm…
Pharma Mar ha recibido un segundo pago de 25 millones de dólares
Pharma Mar hat 2. zahlung von 25 mil $ erhalten
(unos 19 millones de euros) por el cumplimiento de los hitos basados
en el plan de desarrollo de Yondelis en Estados Unidos,
informó hoy la compañía española a la Comisión Nacional del Mercado de Valores (CNMV).

---
charts
vol slowstoch & rsi
http://bigcharts.marketwatch.com/advchart/frames/frames.asp?…
vol faststoch & macd
http://bigcharts.marketwatch.com/advchart/frames/frames.asp?…

[bonDiacomova]

Antwort auf Beitrag Nr.: 42.985.227 von bonDiacomova am 01.04.12 08:47:45

Zeltia, whose stock has lost 80 percent in the past five years, is setting up units in countries including Italy and Germany to gain better access for Yondelis and win licensing agreements for other drugmakers’ cancer treatments,
Chairman Jose Maria Fernandez Sousa-Faro said in an interview - in englisch :
http://www.businessweek.com/videos/2012-04-12/zeltia-says-20…

[bonDiacomova]

vom 09.04. zu Irvalec

After a portfolio review, Spain's Zeltia says its PharmaMar unit has decided
to suspend development of one of its marine-based cancer drugs, Irvalec

The company will put its cash into further development of Yondelis (trabectedin), which is already approved in Europe for advanced soft tissue sarcoma (STS) and relapsed platinum-sensitive ovarian cancer. It is also in Phase III as a first-line treatment of STS.

Two other key drugs for PharmaMar are Aplidin (plitidepsin), which is in Phase III for multiple myeloma and Phase II for T cell lymphoma, and Zalypsis, which is in Phase II for MM and Ewing's sarcoma. Making up the five compounds are two early-stage antitumour agents PM060184 and PM01183, for which impressive preliminary data have been seen.

http://www.pharmatimes.com/Article/12-04-11/Zeltia_ends_Irva…

[bonDiacomova]

J&J Working to Boost Supply of Cancer Drug Doxil by September
http://www.bloomberg.com/news/2012-04-09/j-j-working-to-boos…

---
ich weiss nicht ob es an dieser meldung lag
aber gestern wurden 448.114 st vom shorti gedeckt
insg. short aber noch 7.468.131 st

[bonDiacomova]

http://translate.google.com/translate?hl=de&sl=es&u=http://w…

http://www.cincodias.com/articulo/ciencia-salud/octubre-deci…

sousa

das noch bessere kommt nach yondelis...
i.m. haben wir 2 produkte in fase I und II
welche aus heutiger sicht bessere resultate liefern
als yondelis in den fasen

im oktober wissen wir bezueglich noscira wie es weitergeht
relutate der fase 2 b von nypta gut kann es lizensiert werden
sind sie schlecht wird liqidiert - oder fuer kleingeld verkauft

desweiteren oktober/nov. fase III von yondelis erste anwendung sarkoma
und fase III resultate von aplidin

bon domingo